Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by QS Investors LLC

QS Investors LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 65,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,100 shares during the quarter. QS Investors LLC’s holdings in Halozyme Therapeutics were worth $2,952,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Assetmark Inc. raised its holdings in Halozyme Therapeutics by 32.8% in the 1st quarter. Assetmark Inc. now owns 1,235 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 305 shares during the period. Lazard Asset Management LLC increased its stake in Halozyme Therapeutics by 23.7% during the first quarter. Lazard Asset Management LLC now owns 2,502 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 480 shares during the period. Stephens Inc. AR increased its stake in Halozyme Therapeutics by 377.4% during the first quarter. Stephens Inc. AR now owns 2,530 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,000 shares during the period. Captrust Financial Advisors increased its stake in Halozyme Therapeutics by 32.4% during the first quarter. Captrust Financial Advisors now owns 2,588 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 633 shares during the period. Finally, E Fund Management Co. Ltd. purchased a new stake in Halozyme Therapeutics during the first quarter worth about $130,000. 89.92% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:HALO opened at $36.90 on Thursday. The stock’s 50-day moving average price is $40.60 and its two-hundred day moving average price is $42.70. The company has a current ratio of 8.75, a quick ratio of 8.24 and a debt-to-equity ratio of 6.56. Halozyme Therapeutics, Inc. has a 12-month low of $27.21 and a 12-month high of $56.40. The firm has a market cap of $5.25 billion, a price-to-earnings ratio of 23.65 and a beta of 1.43.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, August 9th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.19. The business had revenue of $136.50 million for the quarter, compared to analyst estimates of $104.08 million. Halozyme Therapeutics had a return on equity of 230.77% and a net margin of 55.45%. The company’s revenue was up 147.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.19 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 1.82 earnings per share for the current fiscal year.

In related news, SVP Michael J. Labarre sold 29,450 shares of the firm’s stock in a transaction dated Friday, October 1st. The stock was sold at an average price of $39.93, for a total transaction of $1,175,938.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jean-Pierre Bizzari sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, August 25th. The shares were sold at an average price of $41.01, for a total value of $1,435,350.00. The disclosure for this sale can be found here. Insiders sold a total of 214,450 shares of company stock worth $8,790,289 over the last ninety days. Corporate insiders own 2.60% of the company’s stock.

A number of brokerages recently issued reports on HALO. Zacks Investment Research downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating and set a $45.00 price target for the company. in a report on Friday, July 16th. TheStreet upgraded Halozyme Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, September 20th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Buy” and an average target price of $51.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Read More: When can a hold rating present a buying opportunity?

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.